Secondary prevention after acute myocardial infarction in four Canadian provinces, 1997-2000.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001955:British Columbia / Q000453:epidemiology; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D023903:Coronary Restenosis / Q000453:epidemiology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D009674:Nova Scotia / Q000453:epidemiology; D009864:Ontario / Q000453:epidemiology; D011322:Primary Prevention / Q000592:standards*; D011379:Prognosis; D011792:Quebec / Q000453:epidemiology; D012042:Registries; D018570:Risk Assessment; D012720:Severity of Illness Index; D016019:Survival Analysis; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers